Search Videos and More

Showing 13 - 24 of 116 results

Previous| 1 | 2 | 3 ...10 |Next


Dana-Farber Brigham Cancer Center Launches New Program for Women with Earliest Form of Breast Cancer News

Dana-Farber Brigham Cancer Center Launches New Program for Women with Earliest Form of Breast Cancer

Dana-Farber Brigham Cancer Center is launching a new program designed to address the unique needs of women diagnosed with the earliest form of breast cancer. Nearly 60,000 women in the United States this year will be diagnosed with Ductal carcinoma in situ (DCIS), a type of breast cancer in which cancerous cells grow but are confined within the milk duct of the breast. The new program will offer DCIS patients outstanding clinical care delivered by Dana-Farber Brigham Cancer Center experts and will be the only such program in Greater Boston offering patients access to clinical trials specific to DCIS.
Researchers Solve Mystery of Retinoic Acid’s Potency Against High-Risk Neuroblastoma News

Researchers Solve Mystery of Retinoic Acid’s Potency Against High-Risk Neuroblastoma

For decades, retinoic acid has been a key part of the arsenal against the childhood cancer neuroblastoma. For just as long, scientists have wondered exactly how it works.
Targeted Drug Shows Activity Against Brain Metastases in Kidney Cancer News

Targeted Drug Shows Activity Against Brain Metastases in Kidney Cancer

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.
Episode 6: Dana-Farber in the Time of COVID Podcast

Episode 6: Dana-Farber in the Time of COVID

A beauty… that in some cases becomes tragic. It's not the way most people would describe a virus. In the simplest of terms, a virus is a snippet of genetic code. It can't reproduce on its own. In order to replicate, it needs to infect and hijack a living cell.
Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes News

Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes

Although stem cell transplantation is the only current therapy with the potential to cure myelodysplastic syndromes (MDS), it is rarely used as an initial treatment for older patients because it hasn’t been proven superior to other therapies. New research by Dana-Farber Cancer Institute investigators stands to overturn that practice.
In Memoriam: David Morse Livingston, MD, Renowned Scientist and Esteemed Mentor News

In Memoriam: David Morse Livingston, MD, Renowned Scientist and Esteemed Mentor

Dana-Farber mourns the loss of David Morse Livingston, MD, renowned scientist and esteemed mentor who not only made key discoveries, but also forged novel collaborations that opened new paths in cancer science.
New Study Finds Link Between Patient Survival and Changes in Tumor Cell Mass in Brain Cancer News

New Study Finds Link Between Patient Survival and Changes in Tumor Cell Mass in Brain Cancer

Researchers at Dana-Farber Cancer Institute and MIT have developed a new way to determine whether individual patients will respond to a specific cancer drug or not.
Mantle Cell Lymphoma Clinical Trial Document

Mantle Cell Lymphoma Clinical Trial

Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.
Faculty Updates News

Faculty Updates

Faculty Updates
Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL) Video

Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)

Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL.
Episode 5: Turning Science Fiction into Fact Podcast

Episode 5: Turning Science Fiction into Fact

It's always fun to think about the future. Flying cars. Cities in the clouds. Colonies on Venus and Mars. OK, we didn't end up living like the Jetsons.
Genetic Signature of Tumor Cells Predicts Response to Chemotherapy Drug for Patients with Form of Ovarian Cancer News

Genetic Signature of Tumor Cells Predicts Response to Chemotherapy Drug for Patients with Form of Ovarian Cancer

For more than two decades, the chemotherapy drug gemcitabine has been a mainstay treatment for several types of cancer, producing remissions in many patients on its own or conjunction with other drugs. Now, scientists at Dana-Farber Cancer Institute have uncovered, for the first time, genetic evidence of which patients with high-grade serous ovarian cancer (HGSOC) are likely to benefit from the drug.

Showing 13 - 24 of 116 results

Previous| 1 | 2 | 3 ...10 |Next